Kodumudi S Balaji

This inventor holds 12 USPTO granted patents and 13 published patent applications, plus 6 CIPO patents and 5 EPO patents. Top assignees: Medicis Pharmaceutical Corporation, Chemo Research, S.l., Watson Laboratories Inc.. Active years: 2012-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kodumudi S Balaji. Retrieved from https://idiyas.com/inventor/kodumudi-s-balaji

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 13)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 57(Granted Patents)

Location History:

Downingtown, PA (US) (2016)
Landsdale, PA (US) (2015 - 2020)
Lansdale, PA (US) (2012 - 2022)

Company Filing History:

8 out of 71

Medicis Pharmaceutical Corporation

Watson Laboratories Inc.

patents

4. 1 out of 27

Watson Pharmaceuticals, Inc.

patents

Years Active: 2012-2022

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11318130 - 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod (2022-05-03),

2. 10596155 - Aqueous-based metronidazole gel formulations (2020-03-24),

3. 10238644 - 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod (2019-03-26),

4. 10238634 - Aqueous-based metronidazole gel formulations (2019-03-26),

5. 9642998 - Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream (2017-05-09),

6. 9370509 - 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod (2016-06-21),

7. 9198858 - Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations (2015-12-01),

8. 9072876 - Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream (2015-07-07),

9. 8946276 - High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis (2015-02-03),

10. 8299109 - Method of treating actinic keratosis with 3.75% imiquimod cream (2012-10-30),

11. 8236816 - 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod (2012-08-07),

12. 8222270 - 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod (2012-07-17),

Title: Innovations by Kodumudi S Balaji in Pharmaceutical Patents

Introduction

Kodumudi S Balaji, based in Lansdale, PA, has made significant contributions to the field of pharmaceuticals, holding a total of 12 patents. His work primarily focuses on developing innovative treatment methods for skin conditions and bacterial infections, enhancing patient care through effective drug delivery systems.

Latest Patents

Among his notable patents, Balaji has developed a 2x2x2 week dosing regimen for treating actinic keratosis. This innovative regimen employs pharmaceutical compositions formulated with 3.75% imiquimod. His inventions also include novel pharmaceutical formulations for the topical or transdermal delivery of imiquimod, targeting actinic keratosis with shorter and more convenient therapy durations than currently prescribed treatments, such as Aldara® 5% imiquimod cream. Another significant innovation involves aqueous-based metronidazole gel formulations, specifically designed for intravaginal applications to effectively treat bacterial vaginosis. These formulations boast an improved safety profile and ease of use, making them a valuable addition to current therapeutic options.

Career Highlights

Throughout his career, Kodumudi S Balaji has been associated with leading pharmaceutical companies, including Medicis Pharmaceutical Corporation and Chemo Research, S.L. His extensive experience in these roles has allowed him to contribute towards the advancement of effective medical treatments, focusing on innovative drug formulations and delivery methods.

Collaborations

Balaji has collaborated with prominent professionals in the industry, including Michael T Nordsiek and Sharon F Levy. These partnerships have facilitated knowledge exchange and fostered the development of groundbreaking solutions in pharmaceuticals.

Conclusion

Kodumudi S Balaji's innovative approach to pharmaceutical formulations has greatly impacted the treatment of various conditions. With his robust portfolio of patents and collaborations with esteemed colleagues, Balaji continues to pave the way for advancements in the medical field, ultimately improving patient outcomes and therapeutic efficacy.

Profile summary based on public USPTO records.